Login to Your Account



EXCLUSIVE RIGHTS TO GI PROGRAMS

Assembly Biosciences poised to get up to $2.78B from Allergan in microbiome deal

By Michael Fitzhugh
Staff Writer

Wednesday, January 11, 2017

Exclusive rights to Assembly Biosciences Inc.'s preclinical gastrointestinal (GI) microbiome programs and additional GI programs secured with a $50 million up-front from Allergan plc could yield a much bigger payday, the company revealed Tuesday.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription